<DOC>
	<DOCNO>NCT00540228</DOCNO>
	<brief_summary>In order find formulation lead maximal increase immune response maintain acceptable safety profile , study design evaluate immunogenicity , safety reactogenicity different formulation GSK Biologicals ' influenza vaccine administer adult age 18-64 year .</brief_summary>
	<brief_title>Study Evaluate Influenza Vaccine Candidate</brief_title>
	<detailed_description>The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Only subject investigator believe comply requirement protocol . A male female , include , 18 64 year age time vaccination . Written inform consent obtain subject . Healthy subject establish medical history clinical examination enter study . If subject female , must nonchildbearing potential childbearing potential , must negative pregnancy test , practice adequate contraception 30 day prior vaccination , continue precaution 2 month completion vaccination series . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within three month prior first vaccine dose Administration vaccine foreseen study protocol 30 day vaccination , 21 day vaccination . History hypersensitivity previous dose influenza vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination History allergic disease reaction likely exacerbate component vaccine ( ) Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Confirmed influenza infection within year precede study start . Administration influenza vaccine within year precede study start . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . Pregnant lactate female . Concurrent participation another clinical study , time study period , subject expose investigational noninvestigational product Acute disease time enrolment . History chronic alcohol consumption and/or drug abuse . Female plan become pregnant planning discontinue contraceptive precaution . Any condition , opinion investigator , prevents subject participate study . History administration experimental/licensed vaccine contain squalene and/or tocopherol within last 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Influenza Vaccine</keyword>
</DOC>